News

The original agreement, executed in 1998, provided Wyeth with access to certain core alphavirus vector technologies controlled by AlphaVax to develop vaccines for selected infectious diseases. The new

Under the extended agreement, Cystic Fibrosis Foundation Therapeutics (CFFT) will provide an additional $22 million to Vertex for continued research funding through early 2008. The first payment is

The new company was founded by former Shire Laboratories president and CEO Jack Khattar, who will retain his job titles at Supernus. Supernus has been funded by the

Source MDx has the ability to analyze biomarkers from a wide variety of samples including a blood sample, which is less invasive than many current clinical tests such

The research team used novel antisense drugs to interrupt normal Ebola virus replication. The findings could serve as the basis for a new approach to quickly develop virus-specific

In their study appearing in the Journal of Clinical Investigation, Giuseppe Matarese and colleagues from Universita di Napoli suggest that leptin neutralization may be a potential way to

These renewable, three-year, master agreements establish a framework for collaboration on a variety of initiatives across a range of AstraZeneca oncology products and research projects. Specific terms of

Under the terms of the agreement, Cold Spring Biotech will market and sell CustomArrays and CatalogArrays, including the recently introduced influenza A research microarray. Cold Spring has three

The new Boston offer for Guidant is worth in the region of $24.8 billion which compares with the Johnson & Johnson offer of $68.06 per share representing a